Home
Conditions
Lymphoproliferative Disorders

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,106 public trials 2,040 recruiting studies

Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Completed

Stem Cell Translpantation in Multiple Myeloma

NCT05082675

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Medizinische Universität Wien Vienna, Austria

Québec, Canada

Rigshospitalet Copenhagen, Denmark

Herlev Hospital Herlev, Denmark

View all 24 locations

View Trial Details

Completed

Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCL

NCT04022005

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations: Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University Guangzhou, Guangdong, China

View Trial Details

Completed

Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma

NCT03338972

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations: Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Completed

Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients

NCT01346787

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: IRCCS CROB UOC di Ematologia e trapianto cellule staminali Ospedale Oncologico Regionale Rionero in Vulture, PZ, Italy

azienda ospedaliero-universitaria umberto I Clinica di Ematologia Ancona, Italy

Policlinico S. Orsola Istituto di Ematologia e Oncologia Medica Bologna, Italy

Ospedale Ferrarotto_Reparto di Ematologia Catania, Italy

View all 13 locations

View Trial Details

Completed

Mobilising Tumour and Immune Cells Via Exercise in Chronic Lymphocytic Leukaemia

NCT05093192

Conditions: Behavior, Chronic Disease, Chronic Lymphocytic Leukemia, +19 more
Locations: Royal United Hospital Bath NHS Foundation Trust Bath, Bath & Northeast Somerset, United Kingdom

University of Bath Bath, Bath & Northeast Somerset, United Kingdom

View Trial Details

Completed

Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma

NCT03733717

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Investigational Site Number 1560003 Beijing, China

Investigational Site Number 1560002 Nanjing, China

Investigational Site Number 1560001 Tianjin, China

View Trial Details

Completed

Evaluation Study on Performance of Guided Clinical Pharmacy Consultation in Patients With Multiple Myeloma on First Oral Anticancer Treatment

NCT04309942

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Nîmes University Hospital Nîmes, Occitanie, France

Dijon University Hospital Pharmacy Dijon, France

Perpignan Hospital Center Perpignan, France

View Trial Details

Completed

Role of Osteocytes in Myeloma Bone Disease

NCT02212262

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Indiana University Simon Cancer Center Indianapolis, Indiana, United States

VA Roudebush Medical Center Indianapolis, Indiana, United States

View Trial Details

Completed

Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

NCT00004197

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +11 more
Locations: Stanford University Medical Center Stanford, California, United States

University of Nebraska Medical Center Omaha, Nebraska, United States

View Trial Details

Completed

Rituxan and BEAM With Autologous Peripheral Blood Progenitor Transplant for Indolent Lymphoma

NCT00572013

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +5 more
Locations: University of Nebraska Medical Center, Section of Oncology/Hematology Omaha, Nebraska, United States

View Trial Details

Lymphoproliferative Disorders

Lymphoproliferative Disorders trial results

Related conditions